OCT 2012

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/87458

Contents of this Issue


Page 131 of 168

For patients with elevated intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) 6–8 mmHg at month 3 5–8 mmHg at month 6 POWERFUL IOP REDUCTIONS > Based on clinical studies of up to 24 months in 905 patients with a baseline pressure of 23–26 mmHg. Once-daily, single-use containers Preservative-free formulation ZIOPTAN is indicated for reducing elevated IOP in patients with OAG or OHT. SELECT IMPORTANT SAFETY INFORMATION ZIOPTAN has been reported to cause changes to pigmented tissues. The most frequently reported changes have been to the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as ZIOPTAN is administered. Pigmentation of the iris is likely to be permanent and may not be noticeable for several months to years, while pigmentation of the periorbital tissue and eyelash changes may be reversible in some patients. The long-term effects of increased pigmentation are not known. ZIOPTAN may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, color, thickness, shape, and number of lashes. Eyelash changes are usually reversible on discontinuation of treatment. ZIOPTAN should be used with caution in patients with active intraocular inflammation (eg, iritis/uveitis) because the inflammation may be exacerbated. Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin F2α analogs. ZIOPTAN should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. In clinical trials of patients receiving either preservative-containing or preservative-free ZIOPTAN, the most common pooled adverse reaction observed was conjunctival hyperemia, which was reported in a range of 4% to 20% of patients. Please see the adjacent Brief Summary of the Prescribing Information. All rights reserved. OPHT-1044142-0009 08/12 Licensed by Santen Pharmaceutical Co., Ltd. Copyright © 2012 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Visit zioptan.com/start1

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld - OCT 2012